Your browser doesn't support javascript.
loading
External Quality Assessment Identifies Training Needs to Determine the Neoplastic Cell Content for Biomarker Testing.
Dufraing, Kelly; De Hertogh, Gert; Tack, Véronique; Keppens, Cleo; Dequeker, Elisabeth M C; van Krieken, J Han.
Afiliação
  • Dufraing K; Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • De Hertogh G; Department of Pathology, University Hospital Leuven, Leuven, Belgium.
  • Tack V; Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
  • Keppens C; Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
  • Dequeker EMC; Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium. Electronic address: els.dequeker@kuleuven.be.
  • van Krieken JH; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
J Mol Diagn ; 20(4): 455-464, 2018 07.
Article em En | MEDLINE | ID: mdl-29625250
Neoplastic cell content determination is crucial for biomarker testing. It is known that interobserver variation exists, but largescale data are missing about variation in tumor delineation and cell content determination. Results were obtained from the external quality assessment program for metastatic colorectal cancer from the European Society of Pathology (N = 5776 observations). The study included three parts: current practices were surveyed, neoplastic cell content estimations and delineations were retrieved from stained slides, and clinical reports were analyzed. Seventeen of 43 pathologists determined the neoplastic cell content in a tumor-rich area for DNA extraction and took immune cells (n = 37), tumor cell distribution (n = 33), desmoplastic stroma (n = 30), necrosis (n = 29), and mucus (n = 23) into account. The selected area was highly variable, and the average difference between the highest and lowest estimation ranged between 51% and 78% (2011 to 2017). The number of overestimations was alarmingly high in samples containing <30% tumor cells. Of concern is that 33 of 105 laboratories reported a wild-type result in a sample without tumor in 2017. Standardization of neoplastic cell content determination is needed for test outcome interpretation. The authors' data show variation in estimation practices, tumor delineations and estimations, and interpretation problems (n = 226 reports). Further training for selecting the most suitable block and creating clear reports is urgently needed.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Garantia da Qualidade dos Cuidados de Saúde / Biomarcadores Tumorais / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Garantia da Qualidade dos Cuidados de Saúde / Biomarcadores Tumorais / Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2018 Tipo de documento: Article